Thalagen is under clinical development by San Rocco Therapeutics and currently in Phase I for Beta Thalassaemia. According to GlobalData, Phase I drugs for Beta Thalassaemia have an 89% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Thalagen’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Thalagen is under development for the treatment of beta-thalassemia. It is administered through the intravenous route. The therapeutic candidate comprises autologous CD34 positive hematopoietic progenitor cells transduced with TNS9.3.55, a lentiviral vector encoding the normal human beta-globin gene.
San Rocco Therapeutics overview
San Rocco Therapeutics (SRT) formerly known as Errant Gene Therapeutics is a healthcare solutions provider. The company develops treatments for life-threatening diseases. It offers therapies for the treatment of lou gehrig’s disease, huntington’s disease, cystic fibrosis, sickle cell anemia and thalassemia.SRT’s thalagen and CG-1521 products are developed for the treatment of the blood disorder thalassemia and refractory prostate cancer. The company’s CG-1521 is an inhibitor of histone deacetylase and represents a treatment paradigm for therapy resistant prostate cancer. It also develops pharmaceutical products for cancer and blood disorders. The company operates its offices in Chicago, Woodland Hills and New York, the US and operates subsidiary in Italy.SRT is headquartered in Chicago, Illinois, the US.
For a complete picture of Thalagen’s drug-specific PTSR and LoA scores, buy the report here.